enzh-CNfrdeitjakorues

Search

Overview

Recce’s New Classes of Synthetic Anti-infectives are designed to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens. Recce Pharmaceuticals have developed two primary drug candidates: RECCE® 327 for bacterial infections and RECCE® 529 for viral infections. RECCE® 529 is a new synthetic polymer formulation with indication against viruses. All RECCE® compounds are 100% water soluble at all pH levels in their liquid form. Recce Pharmaceuticals continues to strengthen and expand their product pipeline in order to find a treatment for ‘difficult to treat’ bacterial and viral infections.

RECCE® 327 - Bacterial Infections

There is a historic lack of innovation in the antibiotic drug development field to address this growing need for effective antibiotics. RECCE® 327 is one of the first new classes of antibiotics in over 30 years with a universal mechanism of action that allow its compounds to continuously kill bacteria and multi-drug resistant superbugs.

What Bacteria has RECCE® 327 demonstrated capability against?

  • bacteria 1 1
    Clostridium difficile
  • bacteria 2 2
    Helicobacter pylori
  • bacteria3
    Streptococcus pyogenes
  • bacteria4
    Neisseria gonorrhoeae
  • bacteria5
    Escherichia coli
  • bacteria6
    Enterococcus faecium
  • bacteria7
    Staphylococcus aureus
  • bacteria8
    Klebsiella pneumoniae
  • bacteria9
    Acinetobacter baumannii
  • bacteria10
    Pseudomonas aeruginosa
  • bacteria11
    Enterococcus species
ESKAPE

ESKAPE Pathogens

Dubbed ESKAPE for their propensity of ‘escaping’ the biocidal action of antibiotics, the acronym stands for six different commonly found multi-drug resistant pathogens: Enterococcus faecium (E. faecium), Staphylococcus aureus (S. aureus), Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii (A. baumannii), Pseudomonas aeruginosa (P. aeruginosa) and Enterobacter species.

An independent study was conducted by a contract research organisation to assess the in vitro efficacy of R327 against all ESKAPE pathogen bacterial strains. The results demonstrated R327 to be 99.9% effective against the full suite of ESKAPE pathogens, within hours of exposure.

RECCE® 529 – Viral Infections

The Company is undertaking initial studies of RECCE® 529 to indicate any potential therapeutic effect against SARS-CoV-2 (the virus causing the disease ‘Coronavirus’ or ‘COVID-19’).

Designed with a Purpose

RECCE® 327's Unique and Multi-layered Mechanism of Action

R327 Mechanism of Action 'unlike that of any antibiotic seen before' with multiple mechanisms identified. R327 rapidly and irreversibly bactericidal against Gram-negative Escherichia coli (E. coli) bacteria, in both active and stationary phase cells - outperforming best in class commercial antibiotics.

Tackling Superbugs

See how R327 tackles superbugs and treats blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.

Sign up for news and updates

Receive news and information direct to your inbox.